MiraDX is a genomics company engaged in the development and commercialization of microRNA-based diagnostic tests. Its products include PROSTOX, a radiogenomics assay for identifying patients who have different sensitivities and responses to radiation therapy; PREVIOTOX, a test that predicts iRAEs to anti-PD1/PDL1 therapy across all cancer types; and a test for determining a KRAS-variant status.